Abbott Laboratories (ABT)
$
131.38
-1.20 (-0.91%)
Key metrics
Financial statements
Free cash flow per share
3.8927
Market cap
228.7 Billion
Price to sales ratio
5.3043
Debt to equity
0.2657
Current ratio
1.8207
Income quality
0.6465
Average inventory
6.8 Billion
ROE
0.2993
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $10,834,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $14,474,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $11,651,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $7.64 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $136.04 appealing to a broad range of investors. With a large market capitalization of $228,661,505,259.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 6,268,226.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Abbott Laboratories stock to fluctuate between $110.86 (low) and $141.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-10-13, Abbott Laboratories's market cap is $228,661,505,259, based on 1,740,459,014 outstanding shares.
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Abbott Laboratories pays dividends. The current dividend yield is 1.80%, with a payout of $0.59 per share.
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
Revenue: $41,950,000,000 | EPS: $7.67 | Growth: 132.42%.
Visit https://www.abbott.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.
seekingalpha.com
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
zacks.com
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
seekingalpha.com
Abbott Laboratories is set to report Q3 earnings, with EPS expectations of $1.30, reflecting 8.3% YoY growth. Abbott's Q2 results showed strong earnings growth, but the stock fell due to expectations of a bigger beat. The company is building a defensible position in the diabetes ecosystem, moving beyond devices to data-driven, integrated care solutions.
zacks.com
Abbott (ABT) reached $134.59 at the closing of the latest trading day, reflecting a +1.2% change compared to its last close.
zacks.com
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
proactiveinvestors.com
UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.
seekingalpha.com
Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristocrats already raising payouts in 2025 at an average rate of 5.19%, nearing last year's pace. 22 Dividend Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
zacks.com
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
zacks.com
In the closing of the recent trading day, Abbott (ABT) stood at $133.89, denoting a -1.47% move from the preceding trading day.
See all news